Interpreting PSA levels correctly: what they show and what they cost

What to expect in this article

1. What the PSA level measures
2. The term that puts everything in order
3. Why a level rises without cancer being present
4. Benefits and harms in numbers
5. What happens to 1,000 men
6. Three statements about the PSA test in a fact check
7. Under what conditions the measurement is taken
8. How a decision is made
9. What a capillary blood test can show here
10. Limitations: what the level does not answer
11. What matters about PSA levels
Frequently asked questions
Sources

What the PSA level measures

The Institute for Quality and Efficiency in Health Care describes the test in one sentence: The test determines the amount of prostate-specific antigen in the blood (as of January 21, 2026).

The term prostate-specific indicates where the substance comes from. It does not say why there is more of it in the blood, and precisely this gap shapes the entire topic.

The level is therefore organ-specific rather than disease-specific. It shows that the prostate is releasing more of this substance and leaves open why.

Why this difference matters so much

With a disease-specific test, interpretation would be simple. A value above the threshold would indicate a disease, while a value below it would not.

That is not how PSA levels work. They rise in several conditions, one of which is cancer and the others are not, and the number itself does not distinguish between these conditions.

This is the basis of the entire discussion surrounding this test. An elevated level leads to further examinations, and some of these examinations concern people who do not have cancer.

The Institute for Quality and Efficiency in Health Care summarizes the situation for laboratory values in general as follows: A single laboratory value usually cannot be used to infer a disease (as of March 20, 2025). For PSA levels, this is not a precautionary formula but the central message.

The term that puts everything in order

One term determines whether the figures for this test become understandable. It appears on the harms side of the screening balance sheet.

An overdiagnosis is a finding that would not have caused symptoms during the person’s lifetime. The cancer is actually present, but it would never have impaired the person affected.

The problem is that this cannot be determined beforehand in an individual case. Someone who receives a diagnosis does not know whether they belong to this group and decides about treatment without that information.

That is precisely why this term appears so prominently in the article. Without it, screening reads like an examination without a downside, and it is not.

Why a value rises without cancer being present

IQWiG names several situations in which the PSA level may be elevated without cancer being present (as of January 21, 2026).

The conditions mentioned include benign enlargement of the prostate, pressure on the prostate, for example after cycling, ejaculation, and a urinary tract infection or inflammation of the prostate.

What this list means in practice

Two of the points mentioned can be influenced before a measurement. A longer bike ride and ejaculation shortly before the sample is taken are things that can be rescheduled.

The other two belong in the interpretation. Benign enlargement of the prostate is common with increasing age, and inflammation is a condition that subsides.

This leads to a simple rule for discussions in medical practices. A single elevated value is a reason to review the circumstances of the measurement, not a diagnosis.

Benefits and harms in figures

The following three figures refer to the same reference group: 1,000 men aged 55 to 69 who participate in screening, followed for 16 years (IQWiG, as of January 21, 2026).

Per 1,000 participating men aged 55 to 69, over 16 years

The three figures are deliberately presented side by side. Anyone who reads only the first sees an examination that saves lives. Anyone who reads only the second sees an examination that causes harm. Together, they constitute the evidence.

What this means for an individual is decided by that person together with their doctor. This article does not make that decision and recommends neither participation nor non-participation.

What happens to 1,000 men

The complete IQWiG breakdown describes what happens to these 1,000 men over the 16 years (as of January 21, 2026).

Of them, 620 have consistently unremarkable values. In 380, the PSA value is elevated at least once. Of these elevated values, 250 lead to a biopsy that finds no cancer, and 130 lead to a cancer finding.

Among the 130 cancer findings are up to 60 cases of overdiagnosis. And within that same group are the approximately 3 men spared metastases and death from prostate cancer.

Why this breakdown is so important

Percentages and relative risk reductions are difficult to grasp. A breakdown that follows 1,000 people over a period of time is easier to understand because it shows all the paths at once.

The relationship between the groups is striking. The largest group among men with elevated values consists of those whose biopsy does not find cancer.

This is not a statement about whether participating is worthwhile. It is a statement about what participation may entail, and this information belongs before the decision.

What a biopsy without a cancer finding means

The term “false positive” sounds like a laboratory error. It means something else: the value was genuinely elevated, but the cause was not cancer.

The possible causes are listed earlier in this article: benign enlargement of the prostate, inflammation, pressure on the prostate, or ejaculation shortly before the sample was taken (IQWiG, as of January 21, 2026).

However, in between is a tissue sample that was taken. It is an intervention, entails a waiting period, and brings with it the anxiety such a waiting period creates.

That is precisely why this figure appears on the harm side of the balance. It describes not a minor detail, but a real event affecting 250 out of 1,000 participants.

Anyone who knows this figure can weigh it against the approximately 3 men spared and decide how much significance to give it. Anyone who does not know it weighs the options without it—and that is the difference at issue here.

Three statements about the PSA test: a fact check

These three statements come up regularly when the test is discussed. All three can be evaluated against the evidence.

Checked against the evidence

The third point applies to every laboratory value, and especially to the PSA value. Problems urinating, blood in the urine or semen, and pain belong in a medical practice, regardless of what a laboratory value shows.

Under what conditions the measurement is taken

The list of causes gives rise to two conditions that can be arranged before a measurement.

The first concerns pressure on the prostate. Because IQWiG explicitly mentions cycling (as of 21 January 2026), a long bike ride should not take place in the days before the sample is collected.

The second concerns ejaculation, which is also included in the list. Here too, the timing of the sample can be chosen so that this explanation is ruled out.

The third condition cannot be arranged, only recorded: a urinary tract or prostate infection. Anyone who has just had one should mention it during the consultation.

The findings note therefore contains four lines: date of sample collection, strenuous physical activity in the preceding days, known inflammation, and all medications. These four lines help determine how an elevated value can be interpreted.

How a decision is reached

For an examination that weighs benefits and harms against each other, there is no universally correct answer. There is an answer for the individual.

Anyone who fears overdiagnosis more than a cancer detected at a late stage will decide differently from someone who weighs the risks the other way around. Both are valid positions, and neither follows from the figures themselves.

What follows from the figures is only the foundation. They belong on the table before a decision is made, which is why this article presents them in full and with their reference population.

The decision itself belongs in a medical consultation. That is where family history, age, existing symptoms, and personal preferences can be considered together—and none of these four things appears in a laboratory report.

The three possible paths after a measurement

Anyone who has their PSA level measured ends up in one of three groups. The table compares them according to the same four criteria, using IQWiG figures for 1,000 participating men aged 55 to 69 over 16 years (as of 21 January 2026).

The last row is the same in all three columns, and that is the table’s key message. None of the three paths ends with a number; all three end with a conversation.

What a capillary blood test can show here

A capillary blood self-test does not detect prostate cancer, rule it out, or replace screening. It provides a number that must be interpreted.

A test by mybody®x (MYBODY Lab GmbH) includes the PSA level among several other measurements. What this means and what it does not is explained in the card.

Blood test using capillary blood

Men’s Wellness Check | Men’s Health Test

Measures 17 values, including prostate-specific antigen, as well as testosterone, cortisol, TSH, the cholesterol profile, homocysteine, liver and kidney values, long-term blood sugar, CRP, ferritin, and vitamin D. What the test does not do: It does not detect prostate cancer, rule it out, or replace a screening examination. It provides a single-point-in-time value, which is interpreted by a medical practice. It does not provide a diagnosis.

Price €169.00 As of 13 August 2026, subject to change

Sample type Capillary blood

Processing time Kit shipping 1–3 business days
Laboratory evaluation 3–5 business days after receipt of the sample

Laboratory Certified medical laboratory
Product page information, accessed 13 August 2026

Go to the Men’s Wellness Check

Four points determine whether a measurement becomes useful information.

Limitations: what the value does not answer

The first limitation is the lack of disease specificity. The value comes from the prostate and does not say why there is more of it in the blood.

The second limitation is overdiagnosis. Up to 60 out of 1,000 participating men receive a diagnosis that would not have caused symptoms during their lifetime, and in individual cases this cannot be determined in advance (IQWiG, as of 21 January 2026).

The third limitation is the thresholds. Regarding the question of the value at which further evaluation should be considered, we found no universally applicable figure in the sources reviewed. That is why none is given in the text; what matters is the reference range of the laboratory performing the analysis together with the doctor’s assessment.

The fourth limitation is the age group. The figures given refer to men between 55 and 69 years of age followed for 16 years. No conclusions can be drawn from them for other age groups.

What matters about the PSA level

If you take away just one thing from this article, let it be this: The PSA level is organ-specific, not disease-specific. It indicates the prostate, not the cause.

This determines how to handle an elevated value. It is a reason to review the circumstances of the measurement and have a conversation, not a diagnosis.

The starting point was the question of how to put the value into context. The most honest answer is: only together with the circumstances, age, medical history, and a doctor’s assessment. No article or self-test can anticipate these four things.

It may seem obvious to object that an article that makes no recommendation is of little help. Here, the opposite is true. In an analysis that weighs benefits and harms against each other, a blanket recommendation would be the most dishonest thing a text could do.

What a text can do is lay all the facts on the table: the approximately 3 men spared, up to 60 overdiagnoses, and 250 biopsies without a cancer finding, in each case per 1,000 participants aged 55 to 69 followed for 16 years (IQWiG, as of 21 January 2026).

This foundation makes it possible to have a conversation that includes your own perspective. Without it, the conversation becomes a question that seems to have only one expected answer.

Frequently asked questions

Sources

1. Institute for Quality and Efficiency in Health Care (IQWiG): The PSA Test for the Early Detection of Prostate Cancer, as of 21 January 2026 – gesundheitsinformation.de
2. Institute for Quality and Efficiency in Health Care (IQWiG): Understanding Laboratory Values Correctly, as of 2 April 2025 – gesundheitsinformation.de
3. Institute for Quality and Efficiency in Health Care (IQWiG): Gamma-GT (GGT), as of 20 March 2025 – gesundheitsinformation.de

The description of what the test measures, the list of causes of elevated values beyond cancer, the verbatim quote about overdiagnosis, the statement that approximately 3 in 1000 men were saved, and the complete breakdown of 620 unremarkable values, 380 elevated values, 250 biopsies without a cancer finding, and 130 cancer findings come from source [1]; the reference population in each case is 1000 men aged 55 to 69 followed for 16 years. The explanation of the reference range and the note about differences between laboratories come from [2]. The statement that a disease usually cannot be inferred from a single laboratory value alone comes from [3]. In the sources reviewed, we found no reliable figure for a generally applicable threshold for further investigation; therefore, none is included in the text. Information on price, values, sample type, and laboratory comes from the mybody®x product page, accessed on 13 August 2026; processing times follow the central specification for blood tests. All sources were accessed and reviewed on 13 August 2026.

mybody®x Editorial & Specialist Team

Laboratory diagnostics Blood analysis interpretation Nutritional science Nutrigenetics

This article was created by the mybody®x editorial and specialist team. The team combines laboratory diagnostics, nutritional science, and the interpretation of blood analyses. Anyone involved can be found on the authors page.

Published on 13 August 2026 · Last updated on 13 August 2026

The content is intended for general information and does not replace medical advice, diagnosis, or treatment. Reference ranges depend on the laboratory, method, and age; the information on your test report is always authoritative.